Found vs IVIM Health vs Remedy Meds (2026)

On tirzepatide, the order is IVIM Health↗ ($278) → Found ($289) → Remedy Meds↗ ($399) — gaps of $11 and then $110 a month, a $1,452 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

IVIM Health: the record, condensed

On tirzepatide, the number that matters at IVIM Health is $278 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Note the shape: $208 is the number in the marketing, $278 is the number at maintenance. The $70 difference is not a fee or a trick per se — it is dose-tiered pricing doing what dose-tiered pricing does — but it means the advertised figure describes month one, not month twelve.

A required $75/month membership is part of the deal, and part of the figure above: $203 of medication plus $75 of platform equals the $278 that leaves your account. Judge the membership by what it includes, but compare on the total.

To place the number: #3 of 17 verified programs, with the floor $63/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $171 a month. A year at this figure: $3,336 monthly-billed.

On semaglutide, the number that matters at IVIM Health is $149 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The figure is quoted at maintenance without a separate teaser tier, which keeps the arithmetic honest by default.

A required $75/month membership is part of the deal, and part of the figure above: $74 of medication plus $75 of platform equals the $149 that leaves your account. Judge the membership by what it includes, but compare on the total.

Context for that figure: it ranks #3 of 20 in the verified semaglutide index — $16/month above the floor (Oak Longevity, $133) — and sits $200 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $1,788.

Operationally at IVIM Health: shipping included; commitment membership mandatory for duration; cancellation membership mandatory; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the IVIM Health page · visit IVIM Health ↗

Found: the record, condensed

Found’s tirzepatide program bills $289 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #6 of 17 verified programs, with the floor $74/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

On semaglutide, the number that matters at Found is $289 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #15 of 20 in the verified semaglutide index — $156/month above the floor (Oak Longevity, $133) — and sits $60 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,468.

Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗

Remedy Meds: the record, condensed

Start with the load-bearing figure: $399 a month, all-in, is what Remedy Meds charges for tirzepatide at the 10 mg basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Remedy Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $399 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #15 of 17 verified programs, with the floor $184/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

Remedy Meds’s semaglutide program bills $299 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Remedy Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $299 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #19 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at Remedy Meds: shipping included; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Remedy Meds page · visit Remedy Meds ↗

§ The three-way read

Prices, gaps, and what sits inside them

IVIM Health holds the low ground at $278 (its $75 membership already inside). Found follows at $289 (+$11/mo, $132/yr). Remedy Meds tops the trio at $399 (+$121/mo over the leader, $1,452/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles nothing: IVIM Health $149 → Found $289 → Remedy Meds $299 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: IVIM Health ($278); cheapest 12-month path: IVIM Health ($3,336); simplest billing (no membership): Found and Remedy Meds; dose-flat structure: Found and Remedy Meds; cheapest semaglutide of the three: IVIM Health ($149).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: IVIM Health vs Found · IVIM Health vs Remedy Meds · Found vs Remedy Meds.

§ Structure, three ways

Everything besides the three prices

Memberships: IVIM Health $75/mo (inside its figure); Found none; Remedy Meds none. Structures: IVIM Health step/tiered; Found dose-flat; Remedy Meds dose-flat. Pharmacies: IVIM Health not named; Found not named; Remedy Meds not named. States: IVIM Health — not published; Found — most states; Remedy Meds — not published. Exit terms: IVIM Health — membership mandatory; Found — membership recurs; prepaid terms are paid up front; Remedy Meds — not published.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: IVIM Health source-verified (2026-08-05); Found third-party reported (2026-08-05); Remedy Meds third-party reported (2026-08-05).

The trio on semaglutide, across time

3 mo: IVIM Health $447 vs Found $867 vs Remedy Meds $897 6 mo: IVIM Health $894 vs Found $1,734 vs Remedy Meds $1,794 12 mo: IVIM Health $1,788 vs Found $3,468 vs Remedy Meds $3,588 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

IVIM Health: $3,336/yr monthly-billed; Found: $3,468/yr monthly-billed; Remedy Meds: $4,788/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $2,904 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

A three-way choice is really two eliminations, so run them in order. Eliminate Remedy Meds first unless it names its edge: at $399 it carries a $121/month premium over the floor of this trio — $1,452 a year, about 5.2 extra months of therapy at IVIM Health’s rate — and a premium that size must point at a specific line in its record (its particular program design) or it is decoration. Then interrogate Found’s middle ground: its dose-flat structure removes titration repricing; if that specific thing is on your personal ledger, the $11/month over the floor can be rational — if not, the middle is where budgets go to leak. What survives is IVIM Health at $278, which wins by default rather than by argument — exactly how a price index should crown things — subject to the two checks no ranking can run for you: your state at intake, and your prescriber on the medication itself.

The same trio on best published rate: IVIM Health $278 → Found $289 → Remedy Meds $399 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — IVIM Health $834, Found $867, Remedy Meds $1,197; 6 months — IVIM Health $1,668, Found $1,734, Remedy Meds $2,394. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

The record-quality read, scored on the five checkable disclosures this index tracks (maintenance price, named pharmacy, published states, published cancellation terms, source-verified capture): IVIM Health 4/5, Found 3/5, Remedy Meds 3/5. IVIM Health discloses the most and Found the least, and in this market disclosure predicts disclosure — the axis where a program goes quiet is reliably where its checkout surprises live. The three match on every disclosure axis, which is rare and worth noting in their favor collectively. Scores recompute from the public records like everything else here.

Read as a decision: start from IVIM Health and make the other two argue upward. Found’s case is its structure; Remedy Meds’s case must be worth $1,452 a year in named features — the honest unit being months of medication (5.2 of them at the floor rate). The pairwise pages above hold each argument in full, and the calculator holds your version of it.